Detecting differential isoform expression from RNA-seq data is one of the common transcriptome analysis tasks. And the purpose of this tutorial is to show you how to perform this analysis on Genestack platform.
With recent advances in NGS technologies, RNA-seq is now the preferred way to measure gene expression and perform differential gene expression analysis. However, the presence of technical variability can lead to a wrong conclusion as shown by the Sequencing Quality Control (SEQC) project, which highlighted the fact that RNA-seq does not accurately measure absolute expression and additionally demonstrated the presence of gene-specific bias. This report will demonstrate the presence of technical bias in several normal tissue RNA-seq experiments and investigate the ability of different normalization methods to address this bias.
The cost and complexity of organising genomics research data are a challenge shared by larger global pharma and growing biotech alike. Dr Misha Kapushesky, CEO of Cambridge-based Genestack, believes that the availability of large scale population studies will intensify this pinch-point. At the upcoming Oxford Global Pharmaceutical IT conference he will be using real world case-studies to describe how effective data management can empower discovery.
As publically funded national population studies begin to produce results, there are increasing opportunities to put private data into a wider context and to mine the multi-omics data for new insights. Dr Misha Kapushesky CEO, Genestack is to discuss the challenges in a presentation at the Oxford Global Pharmaceutical IT Congress on 27-28 September 2017.
During the webinar, Colin Whittaker was discussing: the importance of security assurance for relying parties; different security assurance methods and the reasons for choosing ISO27001; how can relying parties assess the security evidence; how to tailor ISO27001 to smaller enterprises -the process of obtaining ISO27001 certification on the example of Genestack